Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study
- 100 Downloads
This study was to evaluate the surgical and survival effects of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for cervical cancer with stages IB2 to IIB of FIGO 2009 staging.
From February 2, 2001 to November 11, 2015, 428 patients received NAC followed by RH in a tertiary hospital, in which all the major procedures were performed by one surgeon. Surgical and survival outcomes were evaluated between the NAC and primary RH groups.
A total of 279 (65.2%) patients received NAC, and the overall clinical and complete pathological response rates were 65.9% and 10.8%, respectively. Compared with primary RH patients, NAC patients had more advanced stages, higher recurrence rate, longer median duration of RH, and more median estimated blood loss. After adjusted with baseline risk factors, no significant differences in progression-free or overall survival were observed between the NAC and primary RH groups. However, the responders to NAC had better survival outcomes.
There were no surgical or survival benefits of NAC for patients with cervical cancer of stages IB2 to IIB except for the responders to NAC.
KeywordsNeoadjuvant chemotherapy Locally advanced cervical cancer Radical hysterectomy Adjuvant therapy
Locally advanced cervical cancer
Para-aortic lymph nodes
Fluorouracil and cisplatin
Pelvic lymph node
Paclitaxel and carboplatin
Paclitaxel and cisplatin
LL: assistant surgeon, protocol/project development, data management, data analysis, and manuscript drafting; MW: major surgeon and manuscript editing; SM, XT, SZ: assistant surgeons and data management.
This work was supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (no. CAMS-2017-I2M-1-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflicts of interest to disclose.
- 3.deSouza NM, Soutter WP, Rustin G et al (2004) Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome. Br J Cancer 90:2326–2331. https://doi.org/10.1038/sj.bjc.6601870 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Katsumata N, Yoshikawa H, Kobayashi H et al (2013) Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 108:1957–1963. https://doi.org/10.1038/bjc.2013.179 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cervical cancer. Version 2.2019—October 12, 2018. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed 15 Dec 2018
- 12.Gupta S, Maheshwari A, Parab P et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36:1548–1555. https://doi.org/10.1200/JCO.2017.75.9985 CrossRefPubMedGoogle Scholar
- 15.Li L, Ma S, Tan X et al (2019) The urodynamics and survival outcomes of different methods of dissecting the inferior hypogastric plexus in laparoscopic nerve-sparing radical hysterectomy of type C: a randomized controlled study. Ann Surg Oncol 26:1560. https://doi.org/10.1245/s10434-019-07228-8 CrossRefPubMedGoogle Scholar
- 17.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefGoogle Scholar
- 18.Testa AC, Moro F, Pasciuto T et al (2018) PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery. Ultrasound Obstet Gynecol 52:110–118. https://doi.org/10.1002/uog.18953 CrossRefPubMedGoogle Scholar
- 19.Obermair A, Gebski V, Frumovitz M et al (2008) A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol 15:584–588. https://doi.org/10.1016/j.jmig.2008.06.013 CrossRefPubMedGoogle Scholar
- 20.Common Terminology Criteria for Adverse Events (CTCAE) v4.03. National Cancer Institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 15 Dec 2018
- 21.Shimada M, Nagao S, Fujiwara K et al (2016) Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. Int J Clin Oncol 21:1128–1135. https://doi.org/10.1007/s10147-016-1010-0 CrossRefPubMedGoogle Scholar
- 22.Gadducci A, Landoni F, Cosio S et al (2018) Neoadjuvant platinum-based chemotherapy followed by radical hysterectomy for stage Ib2–IIb adenocarcinoma of the uterine cervix—an Italian Multicenter Retrospective Study. Anticancer Res 38:3627–3634. https://doi.org/10.21873/anticanres.12637 CrossRefPubMedGoogle Scholar
- 29.Shoji T, Takatori E, Furutake Y et al (2016) Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass. Int J Clin Oncol 21:1120–1127. https://doi.org/10.1007/s10147-016-1008-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Plante M (2015) Bulky early-stage cervical cancer (2–4 cm lesions): upfront radical trachelectomy or neoadjuvant chemotherapy followed by fertility-preserving surgery: which is the best option? Int J Gynecol Cancer 25:722–728. https://doi.org/10.1097/IGC.0000000000000410 CrossRefPubMedGoogle Scholar
- 38.Lan M, Chen C, Huang Y et al (2017) Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. Sci Rep 7:42624. https://doi.org/10.1038/srep42624 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Ferrandina G, Palluzzi E, Gallotta V et al (2018) Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: a phase II study. Eur J Surg Oncol 44:1062–1068. https://doi.org/10.1016/j.ejso.2018.04.019 CrossRefPubMedGoogle Scholar
- 40.Ferrandina G, Corrado G, Vitrano G et al (2018) Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer Chemother Pharmacol 83:431. https://doi.org/10.1007/s00280-018-3742-1 CrossRefPubMedGoogle Scholar